5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial
Samir Kapadia(Cleveland Clinic), Michael Davidson(University of California, Los Angeles), Vasilis Babaliaros(Valve (United States)), E. Murat Tuzcu(Cleveland Clinic), Michael J. Mack(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Susheel Kodali(Columbia University Irving Medical Center), D. Craig Miller(Harvard University), Lars G. Svensson(Cleveland Clinic), John G. Webb(St. Paul's Hospital), Raj Makkar(Cedars-Sinai Medical Center), Pamela S. Douglas(Duke University), Jodi J. Akin(Edwards Lifesciences (United States)), Howard C. Herrmann(University of Pennsylvania), Gregory P. Fontana(HCA Healthcare), Mathew Williams(Mount Sinai Health System), Martin B. Leon(Columbia University Irving Medical Center), Craig R. Smith(University of Arizona), Wilson Y. Szeto(Mount Sinai Hospital), Vinod H. Thourani(Valve (United States)), Augusto D. Pichard(MedStar Washington Hospital Center), William N. Anderson(Edwards Lifesciences (United States))
Cited by 862
Related Papers
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
|New England Journal of Medicine|2011|6.4k
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
|New England Journal of Medicine|2016|5.1k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.8k
EuroSCORE II
|European Journal of Cardio-Thoracic Surgery|2012|2.9k